Efficacy of Remodulin in Adults With Congenital Heart Disease (ACHD) and Pulmonary Hypertension

Trial Profile

Efficacy of Remodulin in Adults With Congenital Heart Disease (ACHD) and Pulmonary Hypertension

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 25 Sep 2017

At a glance

  • Drugs Treprostinil (Primary)
  • Indications Congenital heart defects; Pulmonary hypertension
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Sep 2017 Status changed from discontinued to withdrawn prior to enrolment.
    • 10 Jun 2017 Biomarkers information updated
    • 29 Jan 2016 Status changed from recruiting to discontinued, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top